Loading
HIV Infections / Depression · Journal article
HIV Research & Clinical Practice · August 6, 2026
Early or partial results. Treat as a signal, not a conclusion.
This small prospective study of 17 people with HIV participating in analytical treatment interruption trials found that health-related quality of life improved significantly over the study period (β = 0.63, p = .016), and that higher baseline resilience moderated steeper HRQOL gains, while baseline depressive symptoms and anxiety were independently associated with lower HRQOL. The findings are preliminary and hypothesis-generating, offering no comparison to non-ATI populations and limited generalizability.
Prospective cohort study with mixed-effects modelling. People with HIV enrolled in two UCSF-based cure-related trials (SCOPE-ATI Study and UCSF-amfAR Combination Trial) requiring analytical treatment interruptions. Intervention: Participation in analytical treatment interruption protocols as part of HIV cure-related trials. n = 17. UCSF centres; specific number of sites and additional centres not stated.
HRQOL improved significantly over time (β = 0.63, p = .016) Baseline depressive symptoms negatively associated with HRQOL (β = -1.00, p = .048) Baseline anxiety negatively associated with HRQOL (β = -1.18, p = .001)
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians conducting HIV cure research with ATI components should proactively screen and address baseline depression and anxiety to optimize participant quality of life and study retention. Resilience assessment may identify participants at risk for HRQOL decline during treatment pauses.
Small single-arm observational study (n=17) showing HRQOL improvement over time in ATI participants, with identified associations between baseline psychosocial factors and trajectories, but lacking a comparator group and powered only for hypothesis generation.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians conducting HIV cure research with ATI components should proactively screen and address baseline depression and anxiety to optimize participant quality of life and study retention. Resilience assessment may identify participants at risk for HRQOL decline during treatment pauses.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background. Although analytical treatment interruptions (ATIs) protocols are essential for evaluating the efficacy of HIV cure-related interventions, little is known about how their health-related quality of life (HRQOL) changes when undergoing these trial requirements.Objective. This study evaluated how HRQOL evolved over time among people with HIV (PWH) participating in HIV cure-related studies requiring ATIs and examined the role of baseline depressive symptoms, anxiety, and resilience in shaping these trajectories.Methods. Seventeen PWH were included. Our analysis included data from two HIV cure-related studies involving ATIs: the UCSF SCOPE-ATI Study and the UCSF-amfAR Combination Trial. HRQOL was measured at baseline, pre-ATI, medication restart, and study completion. Baseline depressive symptoms, trait-based anxiety, and resilience were assessed using validated scales. Frequentist and Bayesian Linear mixed-effects models evaluated changes in HRQOL, the influence of baseline psychosocial factors, and potential moderating effects.Results. In frequentist models, HRQOL significantly improved over time (β = 0.63, p =.016). Baseline depressive symptoms (β = -1.00, p =.048) and anxiety (β = -1.18, p =.001) were negatively associated with HRQOL, indicating that higher levels of these factors were linked to lower HRQOL. Resilience moderated improvements in HRQOL over time (time*resilience β = 0.36, p =.040), with higher baseline resilience associated with steeper increases in HRQOL.Conclusions. HRQOL improved over time in this sample despite ATI participation requirements. Findings underscore the need to address psychosocial factors, particularly depressive symptoms and anxiety, in HIV cure-related studies to optimize participant well-being and enhance the overall study experience.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.